Clinical trial

Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy

NCT07762703

StatusNOT_YET_RECRUITING

Study typeINTERVENTIONAL

Start date2026-09-01

PhasePHASE1 / PHASE2

Study timeline

Study start (estimated)2026-09-01Date precision: month

Registry last updated2026-08-19

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Triple-Negative Breast Cancer (TNBC)unresolved

Interventions

Ipilimumab 2.5 mgDRUG

PembrolizumabDRUG · verified · RxNorm: pembrolizumab

Standard-of-care chemotherapyDRUG

Losartan and aspirinDRUG

Sponsors & collaborators

BreakBio Corplead sponsor

Miami Cancer Institutecollaborator

Mapped research locations

MiamiFlorida, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07762703 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.